Infections in relapsed myeloma patients treated with isatuximab plus pomalidomide and dexamethasone during the COVID-19 pandemic: Initial results of a UK-wide real-world study

Autor: Faouzi Djebbari, Alexandros Rampotas, Grant Vallance, Fotios Panitsas, Nanda Basker, Gina Sangha, Beena Salhan, Farheen Karim, Al-Kaisi Firas, Amy Gudger, Loretta Ngu, Matt Poynton, Ho Pui Jeff Lam, Lowri Morgan, Laura Yang, Jennifer Young, Mairi Walker, Ismini Tsagkaraki, Laura Anderson, Saleena Rani Chauhan, Rebecca Maddams, Richard Soutar, Margarita Triantafillou, Steve Prideaux, Abubaker Obeidalla, Toby A. Eyre, Ceri Bygrave, Supratik Basu, Karthik Ramasamy
Jazyk: angličtina
Rok vydání: 2022
Předmět:
Zdroj: Hematology, Vol 27, Iss 1, Pp 691-699 (2022)
Druh dokumentu: article
ISSN: 16078454
1607-8454
DOI: 10.1080/16078454.2022.2082725
Popis: Objectives There are no real-world data describing infection morbidity in relapsed/refractory myeloma (RRMM) patients treated with anti-CD38 isatuximab in combination with pomalidomide and dexamethasone (IsaPomDex). In this UK-wide retrospective study, we set out to evaluate infections experienced by routine care patients who received this novel therapy across 24 cancer centres during the COVID-19 pandemic.Methods The primary endpoint was infection morbidity (incidence, grading, hospitalization) as well as infection-related deaths. Secondary outcomes were clinical predictors of increased incidence of any grade (G2–5) and high grade (≥G3) infections.Results In a total cohort of 107 patients who received a median (IQR) of 4 cycles (2–8), 23.4% of patients experienced ≥1 any grade (G2–5) infections (total of 31 episodes) and 18.7% of patients experienced ≥1 high grade (≥G3) infections (total of 22 episodes). Median time (IQR) from start of therapy to first episode was 29 days (16–75). Six patients experienced COVID-19 infection, of whom 5 were not vaccinated and 1 was fully vaccinated. The cumulative duration of infection-related hospitalizations was 159 days. The multivariate (MVA) Poisson Regression analysis demonstrated that a higher co-morbidity burden with Charlson Co-morbidity Index (CCI) score ≥4 (incidence rate ratio (IRR) = 3, p = 0.012) and sub-optimal myeloma response less than a partial response (
Databáze: Directory of Open Access Journals
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje